CAS 903565-83-3

Tofogliflozin

Description:

Tofogliflozin is a pharmaceutical compound classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. It works by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in urine and helping to lower blood glucose levels. Tofogliflozin is characterized by its ability to improve glycemic control, reduce body weight, and potentially provide cardiovascular benefits. The compound is typically administered orally and is often used in combination with other antidiabetic medications. Its chemical structure includes a specific arrangement of functional groups that contribute to its pharmacological activity and selectivity for the SGLT2 transporter. As with other SGLT2 inhibitors, common side effects may include urinary tract infections and dehydration. Overall, Tofogliflozin represents a significant advancement in diabetes treatment, offering an alternative mechanism of action compared to traditional therapies.

Formula: C₂₂H₂₆O₆

InChI: InChI=1S/C22H26O6/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22+/m1/s1

InChI key: InChIKey=VWVKUNOPTJGDOB-BDHVOXNPSA-N

SMILES: O[C@H]1[C@]2(C=3C(CO2)=CC=C(CC4=CC=C(CC)C=C4)C3)O[C@H](CO)[C@@H](O)[C@@H]1O

Synonyms:

• (1S,3'R,4'S,5'S,6'R)-6-[(4-Ethylphenyl)methyl]-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2'-[2H]pyran]-3',4',5'-triol
• (1S,3′R,4′S,5′S,6′R)-6-[(4-Ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol
• Csg 452
• R-7201
• Spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, 6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-, (1S,3′R,4′S,5′S,6′R)-
• Tofogliflozin

Tofogliflozin

CAS: 903565-83-3

Formula: C₂₂H₂₆O₆

Color and Shape: Solid

Molecular weight: 386.4382

Ref: IN-DA00GU9J

Tofogliflozin

CAS: 903565-83-3

Formula: C₂₂H₂₆O₆

Molecular weight: 386.45

Ref: 4Z-T-157001

Tofogliflozin

Controlled Product

CAS: 903565-83-3

Applications A novel, potent, and highly selective SGLT2 inhibitor that has been shown to improve glycemic control in diabetic mice and rats.

Formula: C₂₂H₂₆O₆

Color and Shape: Neat

Molecular weight: 386.44

Ref: TR-T528750

Tofogliflozin

CAS: 903565-83-3

Tofogliflozin is a glucose-lowering drug that acts as an inhibitor of sodium-glucose transport (SGLT2) in the proximal tubule. It is used for the treatment of type 2 diabetes mellitus and other metabolic disorders, including hepatic impairment. Tofogliflozin has been shown to be effective for reducing systolic blood pressure in patients with hypertension. This drug also reduces histological evidence of disease activity and p-hydroxybenzoic acid levels in patients with active rheumatoid arthritis or psoriatic arthritis. Tofogliflozin has been shown to increase insulin sensitivity, which may be due to its ability to activate growth factor-β1 and GLP-1 receptors in adipose tissue.

Formula: C₂₂H₂₆O₆

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 386.44 g/mol

Ref: 3D-FT28301

Tofogliflozin

CAS: 903565-83-3

Tofogliflozin specifically inhibits SGLT2; IC50s are 2.9 nM (human), 14.9 nM (rat), 6.4 nM (mouse).

Formula: C₂₂H₂₆O₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 386.44

Ref: TM-T13179